Crestwood Advisors Group LLC Increases Holdings in Zoetis Inc. (NYSE:ZTS)

Crestwood Advisors Group LLC lifted its holdings in Zoetis Inc. (NYSE:ZTS) by 0.3% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 222,338 shares of the company’s stock after acquiring an additional 693 shares during the period. Crestwood Advisors Group LLC’s holdings in Zoetis were worth $43,440,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Prevail Innovative Wealth Advisors LLC raised its position in shares of Zoetis by 24.5% during the first quarter. Prevail Innovative Wealth Advisors LLC now owns 18,977 shares of the company’s stock valued at $3,211,000 after buying an additional 3,738 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S lifted its stake in Zoetis by 58.6% in the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 41,931 shares of the company’s stock worth $7,095,000 after purchasing an additional 15,491 shares in the last quarter. Duality Advisers LP boosted its holdings in shares of Zoetis by 43.7% during the 1st quarter. Duality Advisers LP now owns 40,641 shares of the company’s stock valued at $6,877,000 after purchasing an additional 12,359 shares during the last quarter. M&G Plc purchased a new position in shares of Zoetis during the first quarter valued at about $19,819,000. Finally, Cetera Investment Advisers grew its position in shares of Zoetis by 275.2% during the first quarter. Cetera Investment Advisers now owns 96,085 shares of the company’s stock valued at $16,259,000 after purchasing an additional 70,476 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 0.8 %

Shares of NYSE ZTS traded down $1.37 during mid-day trading on Tuesday, reaching $173.81. The company had a trading volume of 181,599 shares, compared to its average volume of 2,505,110. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92. The business’s 50-day moving average is $188.84 and its 200-day moving average is $179.03. The stock has a market cap of $78.74 billion, a price-to-earnings ratio of 34.28, a price-to-earnings-growth ratio of 2.82 and a beta of 0.90. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32.

Zoetis (NYSE:ZTS) last issued its earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. The business had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The company’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same period last year, the company posted $1.36 earnings per share. Equities analysts expect that Zoetis Inc. will post 5.83 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be issued a $0.432 dividend. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 annualized dividend and a dividend yield of 0.99%. Zoetis’s payout ratio is currently 33.86%.

Analyst Ratings Changes

ZTS has been the topic of a number of research reports. Stifel Nicolaus lifted their price objective on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, September 18th. BTIG Research boosted their price target on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Argus upgraded shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. JPMorgan Chase & Co. boosted their target price on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Finally, Piper Sandler upped their target price on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Zoetis presently has an average rating of “Buy” and an average price target of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.